GSK, Regeneron Covid Antibody Drugs Unlikely to Work for Omicron, WHO Says [Business News Network (BNN) (Canada)]
Vir Biotechnology, Inc. (VIR)
Company Research
Source: Business News Network
subvariants, a panel of experts advising the World Health Organization said, recommending against the use of the medicines. The group's decision comes amid “evidence from laboratory studies that these drugs are not likely to work against currently circulating variants,” the panel said in the medical journal BMJ Friday. The new guideline is a blow to Regeneron, GSK and its partner Vir Biotechnology, replacing a conditional endorsement of the treatments with a “strong recommendation” against their use. But it's not entirely surprising: GSK and Vir's sotrovimab had already lost its US authorization in April because the therapy was unlikely to work against the dominant omicron BA.2 subvariant. Regeneron said the US Food and Drug Administration in January had excluded the use of its Covid antibody cocktail in regions where infections were caused by newer variants, and that the treatment hasn't being used anywhere in the US for some time. The company, meanwhile, is working on “next ge
Show less
Read more
Impact Snapshot
Event Time:
VIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VIR alerts
High impacting Vir Biotechnology, Inc. news events
Weekly update
A roundup of the hottest topics
VIR
News
- Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of Directors [Yahoo! Finance]Yahoo! Finance
- Vir Biotechnology Announces Nomination of Norbert Bischofberger, Ph.D. and Ramy Farid, Ph.D. to its Board of DirectorsBusiness Wire
- Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024 [Yahoo! Finance]Yahoo! Finance
- Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024Business Wire
- Vir Biotechnology Completes Enrollment of Phase 2 Chronic Hepatitis Delta SOLSTICE Trial Ahead of Schedule [Yahoo! Finance]Yahoo! Finance
VIR
Earnings
- 2/22/24 - Beat
VIR
Sec Filings
- 4/18/24 - Form 8-K
- 4/4/24 - Form 4
- 4/4/24 - Form 144
- VIR's page on the SEC website